PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PharmAla Biotech Holdings Inc. has been selected to supply MDMA for a clinical trial at Johns Hopkins Medicine, marking a significant step in supporting US and global research. Additionally, the company has announced the termination of its agreement with Red Light Holland and is set to present its novel molecule, APA-01, at an upcoming European Behavioural Pharmacology Society Workshop, reflecting its ongoing commitment to developing safer MDMA-like compounds.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.